vs

Side-by-side financial comparison of Chatham Lodging Trust (CLDT) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.

Chatham Lodging Trust is the larger business by last-quarter revenue ($67.7M vs $57.6M, roughly 1.2× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -9.8%).

Chatham Lodging Trust is a publicly traded real estate investment trust that invests in, owns, and operates upscale extended-stay and select-service premium hotel properties primarily across high-demand urban and suburban markets in the United States. Its portfolio targets assets with strong occupancy rates and steady cash flow from business and leisure traveler segments.

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

CLDT vs PHAT — Head-to-Head

Bigger by revenue
CLDT
CLDT
1.2× larger
CLDT
$67.7M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+103.9% gap
PHAT
94.1%
-9.8%
CLDT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLDT
CLDT
PHAT
PHAT
Revenue
$67.7M
$57.6M
Net Profit
$4.6M
Gross Margin
86.7%
Operating Margin
15.9%
Net Margin
6.8%
Revenue YoY
-9.8%
94.1%
Net Profit YoY
369.9%
71.6%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLDT
CLDT
PHAT
PHAT
Q4 25
$67.7M
$57.6M
Q3 25
$78.4M
$49.5M
Q2 25
$80.3M
$39.5M
Q1 25
$68.6M
$28.5M
Q4 24
$75.1M
$29.7M
Q3 24
$87.2M
$16.4M
Q2 24
$86.5M
$7.3M
Q1 24
$68.4M
Net Profit
CLDT
CLDT
PHAT
PHAT
Q4 25
$4.6M
Q3 25
$3.5M
$-30.0M
Q2 25
$5.4M
$-75.8M
Q1 25
$1.5M
$-94.3M
Q4 24
$-1.7M
Q3 24
$4.3M
$-85.6M
Q2 24
$6.8M
$-91.4M
Q1 24
$-5.2M
Gross Margin
CLDT
CLDT
PHAT
PHAT
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
40.7%
87.1%
Q3 24
44.7%
85.6%
Q2 24
46.1%
81.2%
Q1 24
38.9%
Operating Margin
CLDT
CLDT
PHAT
PHAT
Q4 25
15.9%
Q3 25
12.7%
-30.8%
Q2 25
14.8%
-151.7%
Q1 25
12.1%
-276.5%
Q4 24
7.5%
Q3 24
14.3%
-433.0%
Q2 24
16.3%
-1055.4%
Q1 24
1.4%
Net Margin
CLDT
CLDT
PHAT
PHAT
Q4 25
6.8%
Q3 25
4.5%
-60.5%
Q2 25
6.7%
-191.9%
Q1 25
2.2%
-330.7%
Q4 24
-2.3%
Q3 24
4.9%
-523.3%
Q2 24
7.9%
-1248.6%
Q1 24
-7.6%
EPS (diluted)
CLDT
CLDT
PHAT
PHAT
Q4 25
$0.05
Q3 25
$0.03
$-0.41
Q2 25
$0.07
$-1.05
Q1 25
$-0.01
$-1.31
Q4 24
$-0.08
Q3 24
$0.05
$-1.32
Q2 24
$0.10
$-1.56
Q1 24
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLDT
CLDT
PHAT
PHAT
Cash + ST InvestmentsLiquidity on hand
$24.4M
$130.0M
Total DebtLower is stronger
$338.9M
$209.1M
Stockholders' EquityBook value
$740.8M
$-438.2M
Total Assets
$1.2B
$259.1M
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLDT
CLDT
PHAT
PHAT
Q4 25
$24.4M
$130.0M
Q3 25
$13.2M
$135.2M
Q2 25
$17.2M
$149.6M
Q1 25
$18.6M
$212.3M
Q4 24
$20.2M
$297.3M
Q3 24
$19.3M
$334.7M
Q2 24
$10.6M
$276.2M
Q1 24
$72.3M
Total Debt
CLDT
CLDT
PHAT
PHAT
Q4 25
$338.9M
$209.1M
Q3 25
$338.8M
$207.1M
Q2 25
$351.2M
$205.1M
Q1 25
$381.1M
$203.2M
Q4 24
$406.9M
$201.4M
Q3 24
$175.7M
Q2 24
$174.4M
Q1 24
Stockholders' Equity
CLDT
CLDT
PHAT
PHAT
Q4 25
$740.8M
$-438.2M
Q3 25
$749.4M
$-422.5M
Q2 25
$754.1M
$-405.8M
Q1 25
$754.7M
$-338.4M
Q4 24
$758.2M
$-253.6M
Q3 24
$765.3M
$-187.1M
Q2 24
$766.5M
$-233.8M
Q1 24
$765.0M
Total Assets
CLDT
CLDT
PHAT
PHAT
Q4 25
$1.2B
$259.1M
Q3 25
$1.2B
$240.3M
Q2 25
$1.2B
$250.2M
Q1 25
$1.2B
$294.2M
Q4 24
$1.3B
$378.3M
Q3 24
$1.3B
$387.0M
Q2 24
$1.3B
$319.4M
Q1 24
$1.3B
Debt / Equity
CLDT
CLDT
PHAT
PHAT
Q4 25
0.46×
Q3 25
0.45×
Q2 25
0.47×
Q1 25
0.50×
Q4 24
0.54×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLDT
CLDT
PHAT
PHAT
Operating Cash FlowLast quarter
$64.1M
$-166.8M
Free Cash FlowOCF − Capex
$-167.0M
FCF MarginFCF / Revenue
-290.0%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
13.90×
TTM Free Cash FlowTrailing 4 quarters
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLDT
CLDT
PHAT
PHAT
Q4 25
$64.1M
$-166.8M
Q3 25
$25.6M
$-14.1M
Q2 25
$22.1M
$-62.7M
Q1 25
$4.2M
$-84.9M
Q4 24
$73.8M
$-266.8M
Q3 24
$28.8M
$-63.6M
Q2 24
$25.2M
$-70.7M
Q1 24
$6.9M
Free Cash Flow
CLDT
CLDT
PHAT
PHAT
Q4 25
$-167.0M
Q3 25
$-14.1M
Q2 25
$-62.8M
Q1 25
$-84.9M
Q4 24
$-266.9M
Q3 24
$-63.6M
Q2 24
$-70.8M
Q1 24
FCF Margin
CLDT
CLDT
PHAT
PHAT
Q4 25
-290.0%
Q3 25
-28.6%
Q2 25
-159.0%
Q1 25
-297.9%
Q4 24
-899.8%
Q3 24
-389.0%
Q2 24
-966.2%
Q1 24
Capex Intensity
CLDT
CLDT
PHAT
PHAT
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.2%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.3%
Q2 24
0.6%
Q1 24
Cash Conversion
CLDT
CLDT
PHAT
PHAT
Q4 25
13.90×
Q3 25
7.24×
Q2 25
4.10×
Q1 25
2.73×
Q4 24
Q3 24
6.78×
Q2 24
3.68×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLDT
CLDT

Occupancy$61.5M91%
Hotel Other$4.2M6%
Food And Beverage$1.8M3%
Hotel$1.1M2%

PHAT
PHAT

Segment breakdown not available.

Related Comparisons